A prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
08 2019
Historique:
received: 13 02 2019
accepted: 11 07 2019
entrez: 29 8 2019
pubmed: 29 8 2019
medline: 8 5 2020
Statut: epublish

Résumé

Development of safe and efficient nanoscale vehicles that can deliver large molecular cargos into human cells could transform future human therapies and personalized medicine. Here, we design a hybrid viral vector composed of a prokaryotic virus (bacteriophage T4) and a eukaryotic virus [adeno-associated virus (AAV)]. The small 25-nm AAV is attached to the large 120 nm × 86 nm T4 head through avidin-biotin cross-bridges using the phage decoration proteins Soc and Hoc. AAV "piggy-backed" on T4 capsid, by virtue of its natural ability to enter human cells acted as an efficient "driver," delivering the largest payloads of foreign DNA (up to 170 kb) and protein (up to 1025 molecules) reported to date, and elicited robust immune responses in mice against flu and plague pathogens and conferred complete protection against lethal pneumonic plague challenge. The T4-AAV represents a unique platform for assembly of natural building blocks into potential therapeutics against genetic and infectious diseases.

Identifiants

pubmed: 31457098
doi: 10.1126/sciadv.aax0064
pii: aax0064
pmc: PMC6703872
doi:

Substances chimiques

Antigens 0
Vaccines, DNA 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaax0064

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI064389
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI056443
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI111538
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI082086
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060549
Pays : United States

Références

J Virol. 2005 Jan;79(2):955-65
pubmed: 15613324
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):E8184-E8193
pubmed: 28893988
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10771-6
pubmed: 23690590
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5846-51
pubmed: 23530211
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):3-26
pubmed: 27473931
mBio. 2018 Oct 16;9(5):
pubmed: 30327445
J Exp Med. 2000 Dec 4;192(11):1545-52
pubmed: 11104797
Front Immunol. 2017 Jun 26;8:687
pubmed: 28694806
Eur J Immunol. 2003 Jun;33(6):1465-70
pubmed: 12778463
J Mol Biol. 1996 May 24;258(5):839-50
pubmed: 8637014
Hum Gene Ther. 2018 Sep;29(9):963-965
pubmed: 30230936
J Mol Biol. 2007 Jul 27;370(5):1006-19
pubmed: 17544446
ACS Synth Biol. 2017 Oct 20;6(10):1952-1961
pubmed: 28657724
Biotechnology (N Y). 1993 Oct;11(10):1138-43
pubmed: 7764094
J Virol. 2008 Jun;82(12):5887-911
pubmed: 18400866
Adv Drug Deliv Rev. 2019 May;145:57-72
pubmed: 29981801
Immunity. 2010 Oct 29;33(4):504-15
pubmed: 21029961
Adv Mater. 2012 Jul 24;24(28):3724-46
pubmed: 22641380
Sci Adv. 2018 Feb 14;4(2):eaar4134
pubmed: 29457136
Acc Chem Res. 2016 Jun 21;49(6):1111-20
pubmed: 27153341
Annu Rev Virol. 2014 Nov;1(1):427-51
pubmed: 26958729
J Virol. 2008 Aug;82(16):7875-85
pubmed: 18524821
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
J Virol. 1998 Feb;72(2):1438-45
pubmed: 9445046
PLoS Pathog. 2013;9(7):e1003495
pubmed: 23853602
Mol Ther. 2006 Jul;14(1):97-106
pubmed: 16624620
Eur J Biochem. 1979 Apr 2;95(2):215-25
pubmed: 456353
Annu Rev Virol. 2015 Nov;2(1):351-78
pubmed: 26958920
J Virol. 2011 Aug;85(16):8141-8
pubmed: 21632759
Nat Immunol. 2004 Oct;5(10):987-95
pubmed: 15454922
Nature. 2016 Oct 12;538(7624):183-192
pubmed: 27734871
Antimicrob Agents Chemother. 2005 Jul;49(7):2874-8
pubmed: 15980363
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17148-53
pubmed: 16284249
Nat Rev Drug Discov. 2011 Jul 01;10(7):521-35
pubmed: 21720407
ACS Nano. 2017 Jan 24;11(1):54-68
pubmed: 28075558
Science. 2015 Sep 18;349(6254):1301-6
pubmed: 26303961
PLoS Biol. 2011 Feb 15;9(2):e1000592
pubmed: 21358801
J Control Release. 2012 Jul 20;161(2):377-88
pubmed: 22516095
Dev Cell. 2001 Aug;1(2):291-302
pubmed: 11702787
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):45-62
pubmed: 26994592

Auteurs

Jingen Zhu (J)

Department of Biology, The Catholic University of America, Washington, DC 20064, USA.

Pan Tao (P)

Department of Biology, The Catholic University of America, Washington, DC 20064, USA.

Marthandan Mahalingam (M)

Department of Biology, The Catholic University of America, Washington, DC 20064, USA.

Jian Sha (J)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.

Paul Kilgore (P)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.

Ashok K Chopra (AK)

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA.

Venigalla Rao (V)

Department of Biology, The Catholic University of America, Washington, DC 20064, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH